Le Lézard
Classified in: Health, Business
Subjects: EXE, AVO

Prime Therapeutics responds to safe harbor proposed rule on prescription drug rebates

EAGAN, Minn., Feb. 6, 2019 /PRNewswire/ -- Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving more than 27 million members nationally, released the following statement from Mike Kolar, its senior vice president and general counsel, in response to the Health and Human Services (HHS) Office of Inspector General's new safe harbor rule proposal to eliminate prescription drug rebates in Medicare Part D:

"We appreciate the Trump administration's desire to address high drug prices for consumers. Prime, too, is committed to being part of the solution to manage consumer out-of-pocket costs, and we work tirelessly every day to lower drug pricing through negotiations with pharmacies and manufacturers. In fact, we are the only leading PBM that is fully transparent with our clients, and whose business model is based upon a full pass through of rebate dollars as a means of controlling overall healthcare costs and premium rates for members.

One thing is clear ?pharmaceutical manufacturers alone set and raise prices. While we carefully review this proposal, our initial view is that this proposal doesn't do anything to mandate or encourage manufacturers to lower their list prices. As the rebate mechanism to help contain pharma's out-of-control price increases is eliminated, we encourage the development of alternate means that will ensure additional tools are available to put similar competitive pressure on manufacturers. This will continue to ensure that premiums and pharmacy counter costs are appropriately managed for beneficiaries.

Beyond the financial impact, the implementation date of Jan. 1, 2020 is highly concerning as bids for Medicare business are due June 1, 2019. This allows less than two months after comments to the rule are due for all PBMs, health plans, manufacturers and pharmacies to comply with the major changes that will be needed. We therefore urge the administration to proceed cautiously, take appropriate time and listen to all stakeholders, otherwise their actions could have unintended consequences for the most important stakeholder in this conversation ? the patient."

About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 27 million people. It is collectively owned by 18 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. For more information, visit www.primetherapeutics.com or follow @PrimePBM on Twitter.


Karen Lyons, APR

Director of Public Relations




SOURCE Prime Therapeutics LLC

These press releases may also interest you

at 08:15
Cardiff Oncology, Inc. , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and...

at 08:15
SourceCast expresses its gratitude for members of the U.S. Armed Forces, their families, and Veterans during National Military Appreciation Month....

at 08:10
Abacus Health Products, Inc. ("Abacus" or the "Company") reported its financial results today for the first quarter ended March 31, 2020. All amounts are in U.S. dollars unless indicated otherwise. Update on Proposed Acquisition of Abacus by...

at 08:09
A majority of job seekers can't capture transferable skills on their resumes or identify how those skills apply to other industries, according to a LiveCareer national survey of 1,519 people left unemployed as a result of the coronavirus pandemic....

at 08:08
New data released today by CAN Capital, Inc., a provider of access to working capital for small and medium sized businesses, shows business owners have a sense of confidence for the future after the COVID-19 crisis. Polling more than 400 U.S. small...

at 08:08
International experts treating COVID-19 patients have concluded that hemodynamic optimization plays a major role in the management of the complex interaction of respiratory and cardiovascular factors. CNSystems, a global market-leader for noninvasive...

News published on 6 february 2019 at 12:00 and distributed by: